NASDAQ : NXTC
NextCure, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.31 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 28.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 28.88M |
| Enterprise Value | 13.46M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.58M |
| Shares Outstanding | 4.58M |
| Shares Change (YoY) | +83.59% |
| Shares Change (QoQ) | +1.35% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 35.79% |
| Float | 2.92M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.47 |
| Quick Ratio | 3.15 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -204.56% |
| Return on Assets (ROA) | -69.02% |
| Return on Invested Capital (ROIC) | -93.24% |
| Return on Capital Employed (ROCE) | -239.55% |
| Weighted Average Cost of Capital (WACC) | 9.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -47.28% |
| 50-Day Moving Average | 6.10 |
| 200-Day Moving Average | 7.85 |
| Relative Strength Index (RSI) | 54.30 |
| Average Volume (20 Days) | 70,667 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 220,966 |
| Short Previous Month | 213,309 |
| Short % of Shares Out | 4.83% |
| Short % of Float | 7.56% |
| Short Ratio (days to cover) | 2.24 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.82M |
| Pretax Income | -42.75M |
| Net Income | -42.75M |
| EBITDA | -37.37M |
| EBIT | -38.82M |
| Earnings Per Share (EPS) | -$9.94 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 20.09M |
| Total Debt | 4.67M |
| Net Cash | 15.42M |
| Net Cash Per Share | $3.37 |
| Equity (Book Value) | 12.15M |
| Book Value Per Share | 2.99 |
| Working Capital | 15.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -36.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.45M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.98M |
| FCF Per Share | -$8.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -83.59% |
| Shareholder Yield | -83.59% |
| Earnings Yield | -157.46% |
| FCF Yield | -128.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.00 |
| Price Target Difference | 216.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |